Clarification regarding fake websites

It has come to the notice of the Ministry of Education that in order to dupe innocent applicants several websites have been created with the name similar to the schemes (like,,  of this Department. 

These websites are offering employment opportunities to the aspiring candidates and misguiding the job aspirants through the layout of website, content and presentation in a manner similar to original website and asking for money from the respondents for the applications. While, these websites have come to the notice of the Department of School Education and Literacy, there may be more such other websites/social media accounts promising jobs and demanding money for recruitment process. 

 The General Public is, hereby, advised to avoid applying for job opportunities on such websites and to ensure themselves that the websites are authorised by visiting the official website of the concerned Department/personal inquiry/telephone call/e-mail to safeguard their own interest. Any person applying on these websites will be doing so at his own risk & cost and shall be responsible for the consequences thereof.



(Release ID: 1803647)
Visitor Counter : 188

Notice Regarding Changes in Representative Corporate Executive Officers


Mitsubishi Chemical Holdings Corporation (MCHC) hereby announces that its Board of Directors meeting today passed a resolution on personnel changes with regard to the Representative Corporate Executive Officer as detailed below.

1. Current and New Representative Corporate Executive Officers

New Position / Current Position / Name

Executive Vice President – Head of Petrochemical and Coal business / Representative Managing Corporate. Executive Officer, Supervising Corporate Strategy, Division, Corporate Communications. Office (Branding) / Yoshihiro Ikegawa

Representative Corporate Executive Officer, Executive Vice President, Chief Supply Chain Officer / Representative Director, Director of the Board, Managing Executive Officer, Supervising- Supply Chains, Mitsubishi Chemical Corporation /Nobuo Fukuda

2. Biography of the New Representative Corporate Executive Officer

Nobuo Fukuda  – (Date of Birth: December 9, 1958  – Number of shares held: 21,074)

1981 Joined Mitsubishi Chemical Industries Limited (currently, Mitsubishi Chemical Corporation)

2012 General Manager, Kurosaki Plant, Mitsubishi Chemical Corporation

2014 Executive Officer, General Manager of Chemical Products, Mitsubishi Chemical Corporation

2021 Representative Director, Director of the Board, Managing Executive Officer supervising- Supply Chains, Mitsubishi Chemical Corporation (current position)

3. Scheduled Date of Personnel Changes

April 1, 2022

4. Reason for the Personnel Changes

Changes in the management structure

In its new management policy “Forging the future” announced on 1 December 2021, MCHC announced its management structure from 1 April 2022. For more details, please refer to the attached press release “4. Leaner Structure to Execute Strategy”.

Corporate Executive Officers of MCHC from 1 April 2022 onwards is shown in the Annex.


Corporate Executive Officers (as of April 1, 2022)

Representative Corporate Executive Officer, President and Chief Executive Officer Jean-Marc Gilson Representative Corporate Executive Officer, Executive Vice President Chief Supply Chain Officer – Nobuo Fukuda

Executive Vice President, Chief Financial Officer Supervising – finance, communication, IR and government affairs – Yuko Nakahira

Executive Vice President, Chief Compliance Officer General Counsel Supervising – legal, internal control, admin, HR and corporate administration – Ken Fujiwara

Executive Vice President Head of Films & Molding Materials / Advanced Solutions Johei Takimoto Executive Vice President Head of Polymers & Compounds / MMA Hitoshi Sasaki Executive Vice President Head of Petrochemical & Coal business – Yoshihiro Ikegawa

Executive Vice President Head of Pharma Hiroaki Ueno Senior Vice President, Chief Technology Officer – Larry Meixner

Senior Vice President Supervising – government affairs –  Shigeki Habuka

Corporate Executive Officers supervising digital and audit will be decided in due course

Notice Regarding Biogen’s Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer’s Disease

Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer’s disease, in countries other than the United States, Japan, and in Europe which have been announced previously.

In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer’s disease. This application is currently in queue for review.

Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted.

Aducanumab is being jointly developed by Biogen and Eisai.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

Topic: Press release summary